Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer

Rhea-AI Summary

Synlogic (Nasdaq: SYBX), a clinical-stage company, announced on September 14, 2020, the appointment of David Hava, Ph.D. as Chief Scientific Officer. Dr. Hava brings over a decade of R&D experience, having previously served as CSO at Metera Pharmaceuticals and Pulmatrix. He will lead research initiatives and expand Synlogic's portfolio of partnerships. The leadership change is expected to enhance the company's Synthetic Biotic platform aimed at treating metabolic disorders and potentially other diseases.

Positive

• Dr. Hava's extensive experience in drug development and partnership building.
• Potential for enhanced strategic direction in Synlogic's research efforts.

Negative

• Concerns regarding leadership continuity and experience gaps after the management change.

CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava, Ph.D. as Chief Scientific Officer. Dr. Hava will provide strategic leadership to the research organization and build Synlogic's portfolio of research partners. Dr. Hava is an experienced drug developer and CSO with a demonstrated track record of taking assets into the clinic and generating partnerships which build clinical and scientific value. He has previously served as Chief Scientific Officer at Metera Pharmaceuticals and Pulmatrix.

"We are thrilled to welcome Dave to the Synlogic executive team. His deep experience in developing drugs and leveraging strategic partnerships will further strengthen our synthetic biology research engine and provide critical scientific vision to support successful advancement of our Synthetic Biotic platform," said Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer.

"I am delighted to join Synlogic. The research team has built the premier scientific and technology platform for engineered bacterial Synthetic Biotic medicines.," said David Hava, Ph.D., Synlogic's Chief Scientific Officer.  "I have great enthusiasm for the potential of these unique medicines to provide clinical benefit. Now is an opportune time for me to join the team given the rapid clinical and preclinical progression of programs against multiple metabolic and immunology targets."

Dr. Hava brings more than a decade of senior experience in research and development to Synlogic, including deep academic expertise in pillars of synthetic biology. Prior to joining Synlogic, David served as CSO at Metera Pharmaceuticals. David has also served as CSO at Pulmatrix Inc., where he led the Research and Development organization in the company's development of their delivery platform. David has co-authored dozens of papers and abstracts focusing on immunology, pulmonary infectious disease and chronic lung diseases, advanced four assets into the clinic, and executed multiple value creating research and clinical partnerships.

Dr. Hava earned his Ph.D. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training at Harvard Medical School studying immunology and host-pathogen interactions.

About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism,  and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View original content to download multimedia:http://www.prnewswire.com/news-releases/synlogic-appoints-david-hava-phd-as-chief-scientific-officer-301128439.html

SOURCE Synlogic, Inc.

FAQ

What is the significance of David Hava's appointment as Chief Scientific Officer at Synlogic?

David Hava's appointment is significant as he brings extensive experience in drug development, which could strengthen Synlogic's research capabilities and partnerships.

How might Dr. Hava's leadership affect Synlogic's Synthetic Biotic platform?

Dr. Hava's leadership is expected to provide scientific vision and strategic direction to enhance the development of Synlogic's Synthetic Biotic medicines.

What experience does David Hava have in the pharmaceutical industry?

David Hava has over a decade of experience in R&D and has served as CSO at other pharmaceutical companies, leading projects into clinical development.

When was David Hava appointed as Chief Scientific Officer of Synlogic?

David Hava was appointed as Chief Scientific Officer on September 14, 2020.